Jump to: Page Content, Section Navigation, Site Navigation, Site Search, Account Information, or Site Tools.
|
|
Copyright © 2006 by Cold Spring Harbor Laboratory Press.
The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1βKsenya Shchors1, Elena Shchors2, Fanya Rostker1, Elizabeth R. Lawlor1,3, Lamorna Brown-Swigart1,, and Gerard I. Evan1,4
1 Cancer Research Institute and Department of Cellular and Molecular Pharmacology, University of California at San Francisco Comprehensive Cancer Center, San Francisco, California 94143, USA; Abstract: Although induction of blood vessel growth is acknowledged as a pivotal requirement for the evolution of macroscopic tumors, the events that trigger onset of tumor angiogenesis remain largely obscure. The pervasive Myc oncoprotein is itself a potent inducer of angiogenesis in a wide range of tissues. We have used a reversibly switchable mouse transgenic model of Myc-dependent β-cell carcinogenesis to delineate the kinetics and causal sequence of angiogenic processes following acute Myc activation. We show that onset of endothelial cell proliferation is induced shortly after Myc-induced cell cycle entry of β cells. Endothelial cell proliferation is not indirectly induced by local tissue hypoxia but instead via a diffusible angiogenic signal produced by Myc-expressing β cells. This signal triggers the release of pre-existing, sequestered VEGF from the islet extracellular matrix, that then homes to the endothelial compartment where it induces endothelial cell proliferation. Myc activation in β cells rapidly induces expression and release of the proinflammatory cytokine interleukin 1β (IL-1β). We show that IL-1β is the principal effector downstream of Myc responsible for triggering rapid onset of islet angiogenesis. Together, our data delineate a complete pathway in vivo by which the highly pleiotropic Myc oncoproteins elicits coexpansion of the vascular compartment during tumorigenic progression.
Key Words: Myc angiogenesis interleukin 1β tumor Received for publication June 6, 2006. Accepted for publication July 26, 2006.
3 Present address: University of Southern California Keck School of Medicine, Children's Hospital Los Angeles, Division of Hematology-Oncology, 4650 Sunset Blvd., Los Angeles, CA 90027-6016, USA E-MAIL gevan{at}cc.ucsf.edu; FAX (415) 514-0878. Supplemental material is available at http://www.genesdev.org. Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1455706.
The editors suggest the following Related Resources on Science sites:In Science Signaling
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
|
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882